Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
| Revenue (Most Recent Fiscal Year) | $5.81B |
| Net Income (Most Recent Fiscal Year) | $412.00M |
| PE Ratio (Current Year Earnings Estimate) | 15.43 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | 0.93 |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.51 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 9.59 |
| Pre-Tax Margin (Trailing 12 Months) | 8.57% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -- |
| Current Ratio (Most Recent Fiscal Quarter) | 2.89 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.33 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.62 |
| Inventory Turnover (Trailing 12 Months) | 0.72 |
| Book Value per Share (Most Recent Fiscal Quarter) | $12.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | $1.69 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Medical Devices |
| Common Shares Outstanding | 437.97M |
| Free Float | 433.59M |
| Market Capitalization | $13.26B |
| Average Volume (Last 20 Days) | 0.87M |
| Beta (Past 60 Months) | 0.69 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 25.64% |
| Annual Dividend (Based on Last Quarter) | $0.89 |
| Dividend Yield (Based on Last Quarter) | 2.95% |